The Business Research Company’s report on the Onpattro Market provides insights into the global market size, growth rate, regional distribution, competitive landscape, key segments, emerging trends, and strategic opportunities.
How have key drivers contributed to the rapid growth of the onpattro market?
The rising prevalence of hereditary transthyretin-mediated amyloidosis is expected to propel the growth of the onpattro market going forward. Hereditary transthyretin-mediated amyloidosis (hATTR) is a rare genetic disorder where mutated TTR proteins form harmful deposits, affecting nerves and the heart. The rising prevalence of hereditary transthyretin-mediated amyloidosis is driven by better diagnostics, genetic testing, and increasing awareness, identifying more cases. Onpattro is used to treat hereditary transthyretin-mediated amyloidosis by silencing the transthyretin (TTR) gene to reduce amyloid protein production and prevent organ damage. For instance, in February 2024, according to Verywell Health, a US-based health information platform, Globally, hereditary transthyretin-mediated amyloidosis affects 5,500–38,500 individuals, with U.S. estimates ranging from 104 to 3,847 cases of hereditary transthyretin-mediated amyloidosis with polyneuropathy, highlighting significant underdiagnosis. Therefore, the rising prevalence of hereditary transthyretin-mediated amyloidosis is driving the growth of the onpattro market.
Access Your Free Sample of the Global Onpattro Market Report – Get Insights Now!
https://www.thebusinessresearchcompany.com/sample.aspx?id=20169&type=smp
How has the onpattro market size evolved, and what are the latest forecasts for its expansion?
The onpattro market size has XX (HCAGR) in recent years. It will grow from $XX million in 2024 to $XX million in 2025 at a compound annual growth rate (CAGR) of XX%. The growth in the historic period can be attributed to the rising prevalence of hereditary transthyretin-mediated amyloidosis, growing awareness of rare diseases, increased research and development investments, an aging population, and rising healthcare expenditure.
The onpattro market size is expected to see XX (FCAGR) in the next few years. It will grow to $XX million in 2029 at a compound annual growth rate (CAGR) of XX%. The growth in the forecast period can be attributed to collaborations and licensing, regulatory support, increasing frequency of chronic diseases, burgeoning biopharmaceutical collaborations, and increasing prevalence of transthyretin amyloidosis cases. Major trends in the forecast period include increasing adoption of ribonucleic acid-based therapies, rise in orphan drug designations, integration of digital health tools, shift toward personalized medicine, and technological advancements in drug delivery.
Gain Exclusive Market Insights—Customize Your Research Report Today For Fast Delivery!
https://www.thebusinessresearchcompany.com/customise?id=20169&type=smp
Which major companies dominate the onpattro market?
Major companies operating in the onpattro market include Alnylam Pharmaceuticals Inc.
What trends will shape the future of the octaplas market?
The key trend in the onpattro market is focused on expanding the drug’s indications through supplemental drug applications, aiming to maximize market potential and meet a wider range of patient needs. Supplemental drug applications generally aim to extend the approved uses of a drug, such as targeting new indications, populations, or formulations, to broaden its therapeutic reach and market potential. For instance, in February 2023, Alnylam Pharmaceuticals, a US-based pharmaceutical company, announced the acceptance of a Supplemental New Drug Application (sNDA) for ONPATTRO (patisiran). This treatment targets cardiomyopathy associated with transthyretin amyloidosis (ATTR). ONPATTRO is an RNA interference (RNAi) therapeutic designed to specifically target the transthyretin (TTR) protein, which can accumulate abnormally in patients with ATTR amyloidosis, leading to severe complications such as cardiomyopathy. The drug was initially approved in 2018 for the treatment of polyneuropathy related to hereditary ATTR amyloidosis. The recent sNDA submission was based on results from the Phase III APOLLO-B study, which demonstrated that patisiran significantly improved functional capacity and quality of life in patients with cardiomyopathy compared to a placebo.
Which region dominates the onpattro market, and what factors contribute to its leadership?
North America was the largest region in the onpattro market in 2024. Asia-Pacific is expected to be the fastest-growing region in the forecast period. The regions covered in the onpattro market report are Asia-Pacific, Western Europe, Eastern Europe, North America, South America, Middle East and Africa.
Order Your Report Now For Swift Delivery
https://www.thebusinessresearchcompany.com/report/onpattro-global-market-report
How is the onpattro market segmented, and which segment holds the largest share?
The onpattro market covered in this report is segmented –
1) By Clinical Indication: Hereditary Transthyretin-Mediated Amyloidosis, Wild-Type Transthyretin Amyloidosis, Other Transthyretin-Related Amyloidoses
2) By Distribution Channel: Direct Sales, Pharmacies, Online Pharmacies
3) By End User: Hospitals, Specialty Clinics, Home Healthcare Providers
Purchase The Exclusive Report Now To Unlock Valuable Market Insights:
https://www.thebusinessresearchcompany.com/purchaseoptions.aspx?id=20169
How is the onpattro market defined?
Onpattro (patisiran) is an FDA-approved medication used to treat hereditary transthyretin-mediated amyloidosis (hATTR), a rare genetic disorder. It works by targeting and silencing the transthyretin (TTR) gene to reduce the production of amyloid proteins that cause organ damage. Onpattro is delivered via intravenous infusion and helps manage symptoms and improve the quality of life for affected patients.
About The Business Research Company:
With over 15000+ reports from 27 industries covering 60+ geographies, The Business Research Company has built a reputation for offering comprehensive, data-rich research and insights. Armed with 1,500,000 datasets, the optimistic contribution of in-depth secondary research, and unique insights from industry leaders, you can get the information you need to stay ahead.
Our flagship product, the Global Market Model, is a premier market intelligence platform delivering comprehensive and updated forecasts to support informed decision-making.
Contact Us:
The Business Research Company
https://thebusinessresearchcompany.com/
Europe: +44 207 1930 708
Asia: +91 88972 63534
Americas: +1 315 623 0293
Email: info@tbrc.info
Follow Us On:
LinkedIn: https://in.linkedin.com/company/the-business-research-company
